VR Therapy for Irritable Bowel Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a virtual reality (VR) cognitive behavioral therapy (CBT) program to determine its effectiveness in reducing abdominal pain and improving daily life for individuals with irritable bowel syndrome (IBS). Participants will use either the new VR program, SynerGI, or a simpler VR experience featuring nature videos. The trial targets individuals diagnosed with IBS who experience significant abdominal pain and have access to a smartphone or computer. As an unphased trial, it offers a unique opportunity to explore innovative therapies that could enhance the quality of life for IBS sufferers.
Will I have to stop taking my current medications?
The trial requires that participants do not take standing doses of opioid medications, as these can affect the gut. If you are on opioids, you may need to stop them to participate.
What prior data suggests that this VR therapy is safe for IBS patients?
Research has shown that virtual reality (VR) therapy is generally safe and easy to handle. Although specific safety information for using VR to treat irritable bowel syndrome (IBS) is lacking, VR treatments are usually considered low-risk. Studies on other conditions have found VR to be safe. For SynerGI, the VR program under testing, similar VR treatments have reported no serious side effects. Most people find VR simple to use and experience no major issues.12345
Why are researchers excited about this trial?
Unlike the standard treatments for irritable bowel syndrome (IBS), which often include medications like antispasmodics, fiber supplements, or dietary changes, SynerGI is unique because it employs virtual reality (VR) technology to deliver cognitive-behavioral therapy (CBT). This innovative approach allows patients to experience a series of interactive virtual environments through the Meta Quest 2 headset, helping them develop coping skills at home over an 8-week period. Researchers are excited about SynerGI because it combines the therapeutic benefits of CBT with the immersive power of VR, potentially offering a non-drug alternative that empowers patients to manage their symptoms more effectively in their daily lives.
What evidence suggests that this VR therapy is effective for irritable bowel syndrome?
This trial will compare two VR therapy approaches for irritable bowel syndrome (IBS). Participants in the SynerGI arm will use a standardized CBT program delivered through a VR device, which has shown promise in reducing stomach pain and improving overall well-being. Meanwhile, the Sham VR arm will offer a distraction-based VR therapy program with 2D nature videos. Studies have shown that VR therapy can help people with IBS by providing a virtual space to learn and practice skills for better condition management. Initial findings suggest that VR therapy addresses not only physical symptoms but also supports mental and social health.12678
Who Is on the Research Team?
Christopher V Almario, MD, MSHPM
Principal Investigator
Cedars-Sinai Medical Center
Are You a Good Fit for This Trial?
This trial is for individuals with significant abdominal pain from IBS, who can read/write English, own a compatible smartphone or computer with internet access. Excluded are those with conditions affecting VR use (like seizures), other GI disorders that could be confused with IBS, opioid medication users, previous VR/CBT trial participants, and those with cognitive impairments.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo an 8-week VR cognitive behavioral therapy (CBT) program or sham VR therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Sham VR
- SynerGI
Find a Clinic Near You
Who Is Running the Clinical Trial?
Christopher Almario
Lead Sponsor
The Cleveland Clinic
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator